Analytical Data
-
Gene name
vif
- Application
-
Alternative Names
vif；Virion infectivity factor
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P69721
-
Expression Region
1-192aa
-
AA Sequence
MENRWQVMIVWQVDRMRIRTWKSLVKHHMYVSGKARGWFYRHHYESPHPRISSEVHIPLGDARLVITTYWGLHTGERDWHLGQGVSIEWRKKRYSTQVDPELADQLIHLYYFDCFSDSAIRKALLGHIVSPRCEYQAGHNKVGSLQYLALAALITPKKIKPPLPSVTKLTEDRWNKPQKTKGHRGSHTMNGH
-
Molecular Weight
38.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Vif (Virion Infectivity Factor) is a key protein produced by the Human Immunodeficiency Virus (HIV) that plays a crucial role in counteracting the antiviral activity of host cellular factors, specifically a class of proteins known as APOBECs (Apolipoprotein B mRNA Editing Enzyme Catalytic Polypeptides). APOBECs can edit the viral DNA during reverse transcription, leading to the incorporation of mutations that severely impair viral replication. However, Vif helps HIV evade this restriction by targeting APOBECs for degradation through the ubiquitin-proteasome pathway, thereby preventing their antiviral effects. The study of Vif and its interactions with host factors is essential for understanding HIV pathogenesis and the molecular mechanisms underlying viral evasion strategies. Research into Vif-recombinant proteins is pivotal for developing novel therapeutic strategies, including potential inhibitors that can restore the antiviral activity of APOBECs or otherwise impede HIV replication. Furthermore, Vif's unique structure and functional attributes make it an attractive target for vaccine design, as understanding its role could lead to innovations in immune responses against HIV. In this context, the recombinant production of Vif has become an important area of study, providing critical insights into its biochemical properties and facilitating the exploration of Vif-targeted interventions in HIV treatment.
